NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against of Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ GM: IMMU). The class action has been filed in the United States District Court, District of New Jersey, on behalf of a class consisting of all persons or entities who purchased Immunomedics common stock between April 20, 2016 and June 2, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Immunomedics is a clinical-stage biopharmaceutical company that researches, develops, manufactures and sells monoclonals and ELISA kits, for use in cancer and autoimmune diagnosis, detection and therapy.

Immunomedics is known for its antibody-drug conjugate sacituzumab govitecan IMMU-132 (“IMMU-132”), currently in Phase II trials for treatment of patients with metastatic triple-negative breast cancer and small-cell and non-small-cell lung cancers.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the abstract for IMMU-132 that Immunomedics submitted to the American Society of Clinical Oncology (“ASCO”) for presentation at the 2016 ASCO Annual Meeting contained outdated results from a mid-stage study; (2) Immunomedics had misrepresented this information to ASCO as if its abstract IMMU-132 only listed updated and previously undisclosed data; (3) the misrepresentation was a violation of ASCO policy and made Immunomedics’ IMMU-132 presentation subject to removal from the 2016 ASCO Annual Meeting schedule; and (4) consequentially, Immunomedics’ public statements were materially false and misleading at all relevant times.

On April 19, 2016, Immunomedics said it would update its results for IMMU-132 treatment for ASCO’s Annual Meeting scheduled in June 2016.

On June 2, 2016, after the market closed, media outlets reported that the American Society of Clinical Oncology (“ASCO”) had removed a scheduled presentation by Immunomedics regarding the Company’s IMMU-132 breast cancer drug from ASCO’s annual meeting. ASCO stated that Immunomedics had misrepresented that the Company’s abstract for IMMU-132 contained updated and previously undisclosed results from a mid-stage study, when in fact the IMMU-132 data that Immunomedics submitted were old and previously seen.

Following this news, Immunomedics stock dropped $0.78, or 14.72%, to close at $4.52 on June 3, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please visit the firm’s site: http://www.bgandg.com/#!immu/sypgi or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Immunomedics you have until August 8, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442275

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court District of New Jersey on behalf of those who purchased shares of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM) and certain of its officers, during the period between March 18, 2013 and June 8, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that Defendants violated Sections 10(b), 14(e) and 20(a) of the Securities Exchange Act of 1934.

Insmed, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapies for patients with serious lung diseases. ARIKAYCE™ (Liposomal Amikacin for Inhalation, or LAI), Insmed’s lead product candidate, is an investigational drug comprising the antibiotic amikacin in the Company’s proprietary liposomal technology formulation. ARIKAYCE is in late-stage clinical development for treatment of serious lung infections such as those caused by nontuberculous mycobacteria (NTM), through delivery of antibiotic directly to the site of the lung infection.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the data supporting Insmed’s European marketing authorization application (“MAA”) for Arikayce was not likely to be approved by the European Medicines Agency (“EMA”) for the treatment of NTM lung disease; (2) Arikayce’s endorsement by the EMA for the treatment of NTM lung disease and subsequent commercialization in Europe were therefore not as likely than Insmed had led its investors to believe; and (3) consequentially, Insmed’s public statements were materially false and misleading at all relevant times.

On June 8, 2016, post-market, Insmed revealed that it had removed Arikayce’s treatment of NTM lung disease MAA from the EMA. Insmed said, “During the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting, the CHMP indicated that the phase 2 study did not provide a sufficient amount of evidence to support an approval. Insmed intends to resubmit its MAA when clinical data from its ongoing global phase 3 study are available.” Following this news, Insmed stock dropped $0.99 per share, or 8.24% to close at $11.02 on June 9, 2016.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/#!insm/iz8zm or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Insmed, you have until September 13, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442518

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ZIOPHARM Oncology, Inc. (“Ziopharm” or the “Company”) (NASDAQ: ZIOP). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.

The investigation concerns whether Ziopharm and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 14, 2016, Ziopharm revealed that a brain cancer patient in an ongoing clinical trial had died after being treated with Ad-RTS-hIL-12, the Company’s experimental gene therapy. A Ziopharm spokesman commented that Ziopharm had not yet informed the U.S. Food and Drug Administration of the death. Ziopharm then disclosed a second death of a patient in clinical study, but said the death was unrelated to Ad-RTS-hIL-12. The Street reported and quoted an email from Jefferies & Co. investment bank to prospective investors, that as a result of the patient death and the way in which Ziopharm had disclosed it, a deal to raise as much as $50 million in a stock offering was abandoned. Following this news, Ziopharm dropped as much as $1.11 per share, or 19.58%, to just $4.56 per share during intraday trading on July 15, 2016.

If you purchased Ziopharm shares or if you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm’s site: http://www.bgandg.com/#!ziop/xauda. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442553

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed on behalf of those who purchased shares of Tangoe, Inc. (“Tangoe” or “the Company”) (NASDAQ GS: TNGO), during the period between March 18, 2014 and March 7, 2016, inclusive (the “Class Period”) This action is pending in the United States District Court for the District of New Jersey.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that Defendants violated Sections 10(b), 14(e) and 20(a) of the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) defendants made errors in recognizing Tangoe’s revenue; (2) the Company’s financial results were overstated; and (3) as a result, statements about Tangoe’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

After market closed on March 7, 2016, the Company issued a press release entitled, “Tangoe Announces That It Will Restate Financial Statements.”

Further, after market closed on March 7, 2016, the Company also filed a Form 8-K with the SEC disclosing the consolidated financial statements of the fiscal years ending December 31, 2013 and 2014, as well as the quarters ended March 31, 2015, June 30, 2015, and September 30, 2015 should no longer be relied upon.

On this news, shares of Tangoe fell $0.70 per share or over 9% from its previous closing price to close at $7.75 per share on March 8, 2016, damaging investors.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator, Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Tangoe, you have until July 25, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442348

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against Oracle Corporation (“Oracle” or “the Company”) (NYSE: ORCL). The class action has been filed in the United States District Court, Northern District of California, on behalf of a class consisting of all persons or entities who purchased Oracle securities during the period between September 16, 2015 and June 1, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Oracle used improper accounting practices to inflate the Company’s cloud computing revenues by millions of dollars; (ii) in violation of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) and the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), Oracle had terminated a Senior Finance Manager for raising the Company’s improper accounting practices to the attention of her supervisors; and (iii) as a result of the foregoing, Oracle’s public statements were materially false and misleading at all relevant times.

On June 1, 2016, after the market closed, media outlets reported that a former Senior Finance Manager at Oracle, Svetlana Blackburn (“Blackburn”), had sued the Company for terminating her for complaining about improper accounting practices in Oracle’s cloud services business. In a complaint filed in U.S. District Court for the Northern District of California, Blackburn accused Oracle’s upper management of trying to push her to “fit square data into round holes” to make Oracle Cloud Services’ results look better. Blackburn’s lawsuit accused Oracle of violating the anti-retaliation provisions of the Sarbanes-Oxley Act and the Dodd-Frank Act and alleged that Blackburn was terminated on October 15, 2015, just one month after the alleged wrongdoing began, and two months after she received a positive performance review.

On this news, Oracle stock fell $1.60, or 3.97%, to close at $38.66 on June 2, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please visit the firm’s site: http://www.bgandg.com/#!orcl/ip9g0 or contact Peretz Bronstein, Esq. or his Investor Relations Coordinator, Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Oracle you have until August 1,
2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442265

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against TransEntrix, Inc. (“TransEntrix” or “the Company”) (NYSE MKT: TRXC). The class action has been filed in the United States District Court, Eastern District of North Carolina, on behalf of a class consisting of all persons or entities who purchased TransEntrix securities during the period between February 10, 2016 and May 10, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements or failed to disclose adverse information regarding key aspects of the Company’s business. Specifically, the complaint alleges defendants failed to disclose deficiencies within the Company’s 510(k) submission regarding the SurgiBot that undermined the likelihood that the SurgiBot would receive FDA clearance, which would leave the Company unable to commercialize the SurgiBot in 2016 and would impair the Company’s ability to obtain approval for and commercialize its other robotic surgery platform in the United States. As a result of these false statements and/or omissions, TransEnterix common stock traded at artificially inflated prices during the Class Period.

On April 20, 2016 post-market, TransEnterix announced that the Food and Drug Administration (“FDA”) informed the Company on the previous day, April 19, 2016, that it has determined that “SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission.” Following this news, TransEnterix’s stock dropped as much as $2.99, or 63.08%, to just $1.75 in after-hours trading on April 20, 2016.

Then on May 20, 2016, the Company issued a press release stating that it “expect[ed] to have further discussion with the FDA, but currently believes that a new 510(k) submission would be required to obtain clearance,” that it was reprioritizing its near-term regulatory efforts to focus on another submission, and that, as a result, it “ha[d] taken actions to reduce headcount and investment related to the SurgiBot.”

Following this news, the price of TransEnterix fell 10% to close at $1.84 per share on May 11, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator, Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Amaya you have until August 1,
2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442269

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court, Southern District of New York on behalf of those who purchased shares of Endo International plc (“Endo” or the “Company”) (NASDAQ: ENDP) between March 2, 2015 and May 6, 2016 inclusive (the “Class Period”).

According to the Complaint, throughout the class period, Endo stated in filings with the U.S. Securities and Exchange Commission (“SEC”) that its net sales for its U.S. Branded Pharmaceuticals segment improved, due to increased proceeds from Frova, Endo’s migraine therapy. Endo’s filings with the SEC included signed certifications that the financial information was correct and revealed any material changes to Endo’s internal control over financial reporting. In Endo’s 2015 Earnings Release, it estimated total revenues between $4.32 billion and $4.52 billion for the year ended December 31, 2016. On March 17, 2016, Endo announced at a conference that its revenue guidance did not meet expectations for the first quarter of 2016, but restated the revenue guidance from the 2015 Earnings Release.

The complaint alleges that Endo officials failed to disclose that its contracts with pharmacy benefit managers (“PBMs”) for Frova included questionable inducements planned increase sales that Endo’s revenues relied on.

On May 5, 2016, Endo announced poor financial results, severely cutting its 2016 guidance, and revealed that the President of the company’s U.S. Branded Pharmaceuticals segment was resigning. Endo also announced that in March of 2016 its subsidiary, Endo Pharmaceuticals Inc., had received a request for documents from the U.S. Attorney’s Office for the Southern District of New York “regarding contracts with Pharmacy Benefit Managers regarding [the migraine treatment] Frova.” Following these news reports, Endo’s stock dropped $11.32 per share, or 42.57%, to close at $15.27 per share on May 9, 2016.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!endo/v6ep3. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Endo you have until July 25, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442276

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed on behalf of those who purchased shares of Unilife Corporation (“Unilife” or “the Company”) (Nasdaq GM: UNIS) between February 3, 2014 and May 23, 2016 inclusive (the “Class Period”).

According to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Unilife’s former Chief Executive Officer and its former Chairman of the Board of Directors had violated Company policies and broken laws and regulations; (2) Unilife lacked sufficient accounting and financial reporting internal controls; (3) consequentially, Unilife would be unable to file its Quarterly Report on Form 10-Q for the period ended March 31, 2016 on time; and (4) subsequently, Unilife’s financial statements, as well as Defendants’ statements regarding Unilife’s business, operations, and prospects, were false and misleading at all relevant times.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!unis/crqg5. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Unilife you have until
July 25, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442278

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against CBL & Associates Properties Inc. (“CBL” or the “Company”) (NYSE: CBL). The class action has been filed on behalf of a class consisting of all persons or entities who purchased CBL common stock between August 8, 2013 and May 24, 2016 (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that CBL made materially false and/or misleading statements and/or failed to disclose material facts about the Company, including that (1) some of its employees may have provided material non-public information to Senator Robert Corker; and (2) the Company failed to disclose to its shareholders that certain of its financing arrangements may have been obtained through fraud and/or misrepresentation.

On May 24, 2016, various news reports published that CBL was being investigated by the FBI and SEC for overstating its properties’ rental income and occupancy charges when providing those figures to banks in financing applications. Following this news, CBL stock dropped roughly 9% on May 25, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please visit the firm’s site: http://www.bgandg.com/#!cbl/jrmj5 or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in CBL you have until July 26, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442272

VANCOUVER, BC / ACCESSWIRE / July 19, 2016 / Far Resources Ltd (CSE: FAT) (FSE: F0R) (“Far Resources” or the “Company“) is pleased to announced that it is planning to expand its drilling to include a drill program on its newly acquired lithium-bearing pegmatite dykes on properties adjacent to its Zoro1 claim in Snow Lake, Manitoba, acquired pursuant to the letter of understanding with Strider Resources Limited (“Strider Resources”) as described in its news release dated July 5, 2016.

Far Resources is planning a program of approximately 1200 metres to confirm some of the historic drill intercepts on the Zoro1 claim as well as testing selected targets on the adjacent Jake claims recently acquired from Strider Resources. The targets in all cases are spodumene-bearing pegmatite dykes.

Representative rock chip samples recently collected by the Company’s consultants from historic trenches exposing these dykes are being analysed by Activation Laboratories of Ancaster, Ontario, an ISO-Certified laboratory. These results will assist in selecting targets and planning the drill program. These assays will be presented in a subsequent news release.

The scientific and technical information regarding Far Resources’ lithium claims contained in this news release has been approved by Mark Fedikow, P.Geo., a consultant of Far Resources and a “qualified person” as defined in NI 43-101.

Frankfurt Stock Exchange Symbol

The Company also wishes to announce that it has been accepted and is now open for trading on the Frankfurt Stock Exchange. The Company will trade under the symbol F0R (F Zero R) and its identifying number, or WKN, is A2AH8W.

About the Company

Far Resources Ltd. is an exploration company, publicly traded on the Canadian Securities Exchange under the symbol FAT, focused on the identification and development of high potential mineral opportunities in stable jurisdictions.

ON BEHALF OF THE BOARD OF DIRECTORS OF
FAR RESOURCES LTD.

Keith C. Anderson, President
604-805-5035

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. All of the forward-looking statements made in this news release are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

SOURCE: Far Resources Ltd

ReleaseID: 442569